From a visionary start-up to a trusted, premier resource for Interferon and Cytokine researchers, PBL Assay Science has proudly provided high quality research-grade products to the scientific community for over three decades. With offerings including highly-specific ELISAs for sensitive detection of both common and lesser known analytes of various species and subtypes, highly active IFN proteins, and application targeted Anti-IFN antibodies, our products have a consistent reputation for providing accurate and reliable results.
Recombinant Human IFN-Lambda 1 protein (Human IL-29) expressed in human cells (HCE).
Human Interferon Alpha 17 recombinant protein expressed in E.coli.
With a 10-fold greater specific activity than the E.coli derived protein, this authentic sequence of Mouse IFN-Beta protein is glycosylated and has no tag.
This Mouse monoclonal antibody against Human Interferon Gamma Receptor Chain 2 (Clone MMHGR-2) is suitable for use in Direct Binding ELISA
Recombinant Rat Interferon Alpha 14 (IFNa14) expressed in mammalian cells with activity measured on rat epithelial-like cells (RATEC).
Rabbit polyclonal antibody against Human Interferon Gamma suitable for use in neutralization, Western Blot, immunoprecipitation, immunohistochemistry, and ELISA
Monoclonal and polyclonal antibodies are often interchangeable; however in some applications, one or the other antibody will give a better result.
Monoclonal antibodies (MAbs) are monospecific antibodies that are the same because they are made by identical immune cells that are all clones of a unique parent cell. MAbs have monovalent affinity, in that they bind to the same epitope and offer high specificity in applications such as ELISA, flow cytometry or epitope mapping where specific binding is desirable.
PBL’s MAbs are derived against a range of interferons from various mammalian species. They deliver superior product stability and high specificity while providing reliable and reproducible results.
Catalog No. | Description | Pack size |
21100-1 | Anti-Human IFN-Alpha, Clone MMHA-2 (MAb) | 50 μg |
21100-2 | Anti-Human IFN-Alpha, Clone MMHA-2 (MAb) | 500 μg |
21105-1 | Anti-Human IFN-Alpha, Clone MMHA-1 (MAb) | 50 μg |
21110-1 | Anti-Human IFN-Alpha, Clone MMHA-8 (MAb) | 50 μg |
21112-1 | Anti-Human IFN-Alpha, Clone MMHA-11 (MAb) | 50 μg |
21116-1 | Anti-Human IFN-Alpha, Clone MMHA-13(MAb) | 50 μg |
21118-1 | Anti-Human IFN-Alpha, Clone MMHA-17 (MAb) | 50 μg |
21125-1 | Anti-Human IFN-Alpha, Clone MMHA-6 (MAb) | 50 μg |
21127-1 | Anti-Human IFN-Alpha, Clone MMHA-9 (MAb) | 50 μg |
21129-1 | Anti-Human IFN-Alpha, Clone MMHA-14 (MAb) | 50 μg |
Catalog No. | Description | Pack size |
21400-1 | Anti-Human IFN-Beta, Clone MMHB-3 (MAb) | 50 μg |
21405-1 | Anti-Human IFN-Beta, Clone MMHB-1 (MAb) | 50 μg |
21410-1 | Anti-Human IFN-Beta, Clone MMHB-2 (MAb) | 500 μg |
21450-1 | Anti-Human IFN-Beta, Clone MMHB-12 (MAb) | 50 μg |
21455-1 | Anti-Human IFN-Beta, Clone MMHB-13 (MAb) | 50 μg |
21460-1 | Anti-Human IFN-Beta, Clone MMHB-14 (MAb) | 50 μg |
21465-1 | Anti-Human IFN-Beta, Clone MMHB-15 (MAb) | 50 μg |
21470-1 | Anti-Human IFN-Beta, Clone MMHB-16 (MAb) | 50 μg |
Catalog No. | Description | Pack size |
21370-1 | Anti-Human IFN-Alpha/Beta Receptor 1 Antibody, Clone MMHAR-3 | 50 μg |
21385-1 | Anti-Human IFN-Alpha/Beta Receptor Chain 2, Clone MMHAR-2 (MAb) | 50 μg |
21585-1 | Anti-Human IFN-Gamma Receptor Chain 2, Clone MMHGR-2 (MAb) | 250 μg |
21885-1 | Anti-Human IFN-Lambda Receptor 1, Clone MMHLR-1 (MAb) | 50 μg |
Catalog No. | Description | Pack size |
22100-3 | FITC Conjugated Anti-Mouse IFN-Alpha, Clone RMMA-1 (MAb) | 25 μg |
Polyclonal antibodies (PAbs) are obtained using a mixture of immunoglobulin molecules secreted against a specific antigen, each recognizing a different epitope making them more tolerant to small changes in the structure of the antigen. PAbs are preferable for neutralization because they target a variety of specific epitopes of a particular antigen.
PBL’s PAbs are available for use in a range of applications including ELISA, neutralization assays, western blotting, flow cytometry, immunoprecipitation, and immunohistochemistry.
Catalog No. | Description | Pack size |
31101-1 | Anti-Human IFN-Alpha, Rabbit Serum (PAb) | 1 x 10⁵ units |
31110-1 | Anti-Human IFN-Alpha, Sheep Serum (PAb) | 1 x 10⁵ units |
31135-1 | Anti-Human IFN-Alpha (All Subtypes), Rabbit Serum (PAb) | 1 x 10⁵ units |
31401-1 | Anti-Human IFN-Beta, Sheep Serum (PAb) | 2 x 10⁴ units |
31405-1 | Anti-Human IFN-Beta, Rabbit IgG, protein A purified (PAb) | 2 x 10⁴ units |
31410-1 | Anti-Human IFN-Beta, Rabbit Serum (PAb) | 2 x 10⁴ units |
31420-1 | Anti-Human IFN-Beta, Goat IgG, Affinity Purified (PAb) | 100 μg |
31500-1 | Anti-Human IFN-Gamma, Rabbit Serum (PAb) | 2 x 10⁴ units |
39000-1 | Human Type I IFN Neutralizing Antibody Mixture | 0.2 ml |
Catalog No. | Description | Pack size |
32100-1 | Anti-Mouse IFN-Alpha, Rabbit Serum (PAb) | 2 x 10⁴ units |
32120-1 | Anti-Mouse IFN-Alpha, Chicken IgY, Purified (PAb) | 500 μg |
32400-1 | Anti-Mouse IFN-Beta, Rabbit Serum (PAb) | 2 x 10⁴ units |
32401-1 | Anti-Mouse IFN-Beta, Rabbit IgG, Protein A purified (PAb) | 2 x 10⁴ units |
32500-1 | Anti-Mouse IFN-Gamma, Rabbit Serum (PAb) | 2 x 10⁴ units |
With over 30 years of experience developing and manufacturing recombinant proteins for life science research, our manufacturing and quality standards ensure that our proteins exhibit lot-to-lot consistency, as well as high levels of bioactivity, high purity, and low endotoxin levels.
Many of our proteins are sold as units of activity per vial instead of in units of mass per vial (µg or mg). Each new lot of protein is tested internally using the same bioassay to provide a valid activity comparison between lots. (ED50 is the amount of protein required to elicit a 50% maximum response in the bioassay.) Providing our proteins by activity instead of mass ensures that your results are biologically relevant.
Cytokines are a class of signaling proteins that play a role in both the induction and effector phases of all immune and inflammatory responses, including cell proliferation, intercellular communication, and cell death. Cytokines are produced by a variety of hematopoietic and non-hematopoietic cell types and can exert autocrine and paracrine effects. They are related more correctly to hormones than to growth factors in their overall functions, but many cytokines also exhibit growth factor activity.
Growth factors are proteins that bind to receptors on the cell surface, with the primary result of activating cellular proliferation and/or differentiation. Growth factors are important for regulating a variety of cellular processes and are quite versatile, stimulating cellular division in numerous different cell types; while others are specific to a particular cell-type.
Catalog No. | Description | Pack size |
11965-1 | Human IFN-Alpha Multi-Subtype ELISA Kit (Serum, Plasma, TCM) | 500 units |
Human Cell Expressed (HCE) cytokines closely mimic native human proteins. These affordable, tag-free, animal-component-free proteins are produced in stable, serum-free, chemically defined cell culture helping ensure lot-to-lot consistency and reproducibility.
HCE cytokines possess authentic human N-and/or O-linked glycosylation and other post-translational modifications preserving appropriate biological activities and epitopes. These proteins retain native properties and accurately mimic native human proteins, providing researchers a useful tool to use in human cell culture experiments.
Catalog No. | Description | Pack size |
11720-1 | Human IFN-Lambda 2, Human Cell Expressed | ≥ 1 x 10⁵ units |
11730-1 | Human IFN-Lambda 3, Human Cell Expressed | ≥ 1 x 10⁵ units |
11725-1 | Human IFN-Lambda 1, Human Cell Expressed | ≥ 1 x 10⁵ units |
11701-1 | Human Interleukin 22 (Human Cell-Expressed) | 10 μg |
11701-2 | Human Interleukin 22 (Human Cell-Expressed) | 50 μg |
11702-1 | Human Interleukin 15 / IL-15Rα Heterodimer (Human Cell-Expressed) | 10 μg |
11702-2 | Human Interleukin 15 / IL-15Rα Heterodimer (Human Cell-Expressed) | 50 μg |
PBL offers a range of interferons from different species and of different classes including multiple IFN-Alpha and IFN-Beta subtypes. Our interferons are high purity, provide consistent performance and biological activity, and are suitable for use in a range of research applications.
Human IFN-Alpha proteins are found as multiple subtypes produced by a viral infection, immune stimulators, and chemical inducers. These type I interferon alpha proteins differentially exhibit antiviral, antiproliferative, and immunomodulatory activities. When interferon alpha interacts with its cognate receptor, a signal is rapidly transmitted within the cell, often producing an antiviral state. The primary signal transduction cascade promoted by type I interferons is the JAK1-STAT pathway. Activation of this cascade leads to increased expression of a large number of genes, including (2′-5′) oligoadenylate synthetases, Mx proteins, and protein kinase R (PKR) that protect the cell from viral infection. Interferon Alpha 2a and Alpha 2b are the most widely used therapeutic interferon alpha proteins, and have been modified with polyethylene glycol sidechains to yield therapeutic interferons with extended half-lives.
First approved for the treatment of Hairy Cell Leukemia, interferon alpha has been utilized extensively as a therapeutic intervention to treat patients with Hepatitis B, Hepatitis C, Melanoma, and T-cell Lymphoma. Though the detailed biological mechanisms responsible for the actual and potential therapeutic activities and varied biological sequelae of each of the type I interferon alpha subtypes are not well defined in most cases, this family of interferon proteins comprises an important area of life science and therapeutic investigation.
Catalog No. | Description | Pack size |
11200-1 | Universal Type I IFN (Human IFN-Alpha Hybrid Protein) | 1 x 10⁵ units |
11200-2 | Universal Type I IFN (Human IFN-Alpha Hybrid Protein) | 1 x 10⁶ units |
11002-1 | Human IFN-Alpha Sampler Set | 1 x 10⁵ units |
11100-1 | Human IFN-Alpha 2a (Alpha A) Protein | 5 x 10⁶ units |
11101-1 | Human IFN-Alpha 2a (Alpha A) Protein, Carrier-Free | 5 μg |
11101-2 | Human IFN-Alpha 2a (Alpha A) Protein, Carrier-Free | 20 μg |
11105-1 | Human IFN-Alpha 2b (Alpha 2) Protein | 1 x 10⁵ units |
11115-1 | Human IFN-Alpha 8 (Alpha B2) Protein | 1 x 10⁵ units |
11120-1 | Human IFN-Alpha 10 (Alpha C) Protein | 1 x 10⁵ units |
11125-1 | Human IFN-Alpha 1 (Alpha D) Protein | 1 x 10⁵ units |
11130-1 | Human IFN-Alpha 21 (Alpha F) Protein | 1 x 10⁵ units |
11135-1 | Human IFN-Alpha 5 (Alpha G) Protein | 1 x 10⁵ units |
11145-1 | Human IFN-Alpha 14 (Alpha H2) Protein | 1 x 10⁵ units |
11150-1 | Human IFN-Alpha 17 (Alpha I) Protein | 1 x 10⁵ units |
11160-1 | Human IFN-Alpha 7 (Alpha J1) | 1 x 10⁵ units |
11165-1 | Human IFN-Alpha 6 (Alpha K) Protein | 1 x 10⁵ units |
11175-1 | Human IFN-Alpha D (Alpha 1) Protein | 1 x 10⁵ units |
11177-1 | Human IFN-Alpha 4a (Alpha M1) Protein | 1 x 10⁵ units |
11180-1 | Human IFN-Alpha 4b (Alpha 4) Protein | 1 x 10⁵ units |
11190-1 | Human IFN-Alpha 16 (Alpha WA) Protein | 1 x 10⁵ units |
Human IFN-Beta protein expression and secretion is primarily induced by signaling from pattern recognition receptors such as Toll-like (TLR) and RIG-I-like receptors (RLR). Overall, IFN-beta is part of the first wave of cytokine response in cells. Pathogen infection can result in the activation of interferon regulatory factor (IRF3) that functions in trans to activate IFN-beta gene transcription. IFN-beta is biologically unique when compared to other interferons. Studies have shown that IFN-beta has overlapping and distinct gene expression patterns as compared to IFN-alpha. It appears that IFN-beta binds to the Type I IFN receptor (IFNAR) with higher affinity than other Type I IFNs and that it may also regulate receptor internalization in a different manner.
Various Type II and III Interferon proteins.
Catalog No. | Description | Pack size |
11720-1 | Human IFN-Lambda 2, Human Cell Expressed | ≥ 1 x 10⁵ units |
11730-1 | Human IFN-Lambda 3, Human Cell Expressed | ≥ 1 x 10⁵ units |
11725-1 | Human IFN-Lambda 1, Human Cell Expressed | ≥ 1 x 10⁵ units |
11395-1 | Human IFN-Omega | 25 μg |
11821-1 | Human IL-28A/IFN-Lambda 2, Carrier-Free | 25 μg |
11826-1 | Human IL-29/IFN-Lambda 1, Carrier-Free | 25 μg |
11500-1 | Human IFN-Gamma | 50 μg |
11500-2 | Human IFN-Gamma | 100 μg |
Mouse Interferon Alpha, Beta, and Lambda proteins.
Interferons (IFNs) are a group of cytokines which exhibit pleitropic activities that play major roles in both innate and adaptive immunity. Type I IFNs consist of multiple IFN-alpha (IFN-α) genes and at least one IFN-beta (IFN-β) gene in most vertebrates, and a few other family members such as limitin in the mouse. There are 14 IFN-alpha subtypes in the mouse which share at least 75% identity in protein sequence. In the human, IFN-alpha is used to treat viral diseases and cancer and is studied in mouse models of these diseases. Recent evidence has suggested that IFN-alpha may play a role in development of certain autoimmune diseases and that treatment with IFN-alpha is useful for other autoimmune diseases.
Catalog No. | Description | Pack size |
12100-1 | Mouse IFN-Alpha A | 1 x 10⁵ units |
12105-1 | Mouse IFN-Alpha 1 | 1 x 10⁵ units |
12115-1 | Mouse IFN-Alpha 4, mammalian | 1 x 10⁵ units |
12125-1 | Mouse IFN-Alpha 11 | 1 x 10⁵ units |
12130-1 | Mouse IFN-Alpha 13 | 1 x 10⁵ units |
Interferon Beta plays a pivotal role in the protective response to many infections and diseases due to its antiviral and immune-modulatory activities, and is an important early product of TLR/RLR stimulation. However, when produced unchecked it can also contribute to the generation of clinically relevant side effects and pathological processes. Additionally, IFN-β is a common therapeutic treatment for multiple sclerosis and some cancers with the research into these diseases often conducted in mice.
Catalog No. | Description | Pack size |
12405-1 | Mouse IFN-Beta, Mammalian | 1 x 10⁵ units |
12410-1 | Mouse IFN-Beta, Mammalian, Carrier-Free | 1 x 10⁶ units |
12400-1 | Mouse IFN-Beta, E.Coli | 1 x 10⁵ units |
12401-1 | Mouse IFN-Beta, Carrier-Free | 1 x 10⁵ units |
Interferon Beta plays a pivotal role in the protective response to many infections and diseases due to its antiviral and immune-modulatory activities, and is an important early product of TLR/RLR stimulation. However, when produced unchecked it can also contribute to the generation of clinically relevant side effects and pathological processes. Additionally, IFN-β is a common therapeutic treatment for multiple sclerosis and some cancers with the research into these diseases often conducted in mice.
Catalog No. | Description | Pack size |
12405-1 | Mouse IFN-Beta, Mammalian | 1 x 10⁵ units |
12410-1 | Mouse IFN-Beta, Mammalian, Carrier-Free | 1 x 10⁶ units |
12400-1 | Mouse IFN-Beta, E.Coli | 1 x 10⁵ units |
12401-1 | Mouse IFN-Beta, Carrier-Free | 1 x 10⁵ units |
Catalog No. | Description | Pack size |
51100 | iLite Human Type I IFN Responsive Cells | 2.5 ml/vial |
PBL Assay Science’s Interferon (IFN) ELISA kits are designed to provide accurate and reproducible quantitation of IFNs in samples from human, mouse, and other species. They have been cited in high impact journals by IFN & Cytokine researchers for over three decades.
VeriKine-HS Human IFN-Alpha ELISA (All-Subtype) kits are designed to provide low pg/ml (LOQ 1.95 pg/ml) sensitivity and global IFN-Alpha subtype detection (12 of 12) in serum, plasma, and tissue culture media (TCM). As multiple IFN-Alpha (IFNa, IFN-a) species are often present in biological samples, the ability to determine the total amount of IFN-Alpha subtypes is integral to a full understanding of IFN-Alpha’s role within the immune system.
If you have questions regarding the need for global IFN-Alpha subtype measurement with regard to your specific research, PBL would be happy to help you choose an ELISA that will work best for you. Please contact us to discuss any concerns you may have!
Product Catalog No. | 41135 | 41115 |
High Sensitivity for low-level Human IFN-Alpha quantification | 1.95 – 125 pg/ml | |
Human IFN-Alpha All-Subtype reactivity for total quantification |
12 of 12 (Hu IFN-Alpha Subtype Specificities chart) |
|
Robust Sample Matrix Compatibility | Tissue Culture Media (TCM) | TCM; EDTA-Plasma; Healthy and Autoimmune Disease Sera |
PBL’s multi-subtype ELISAs (41100, 41105, 41110) detect a number of the 12 IFN-Alpha subtypes. These kits differ in three main ways from one another: (1) subtype detection (moderately sensitive for most or several IFN-Alpha subtypes), (2) assay range, and (3) matrix compatibility (TCM, serum, plasma).
Catalog No. | Description | Pack size |
41110-1 | Human IFN-Alpha Multi-Subtype ELISA Kit (Serum, Plasma, TCM) | 1 x 96-well plate |
41110-2 | Human IFN-Alpha Multi-Subtype ELISA Kit (Serum, Plasma, TCM) | 5 x 96-well plates |
41105-1 | Human IFN-Alpha Multi-Subtype ELISA Kit (TCM) | 1 x 96-well plate |
41105-2 | Human IFN-Alpha Multi-Subtype ELISA Kit (TCM) | 5 x 96-well plates |
41100-1 | Human IFN-Alpha ELISA Kit (TCM) | 1 x 96-well plate |
41100-2 | Human IFN-Alpha ELISA Kit (TCM) | 5 x 96-well plates |
41115-1 | Human IFN-Alpha All Subtype ELISA Kit, High Sensitivity (Serum, Plasma, TCM) | 1 x 96-well plate |
41135-1 | Human IFN-Alpha All Subtype ELISA Kit, High Sensitivity (TCM) | 1 x 96-well plate |
These Human IFN-Beta ELISAs are highly sensitive immunoassays (< 3 pg/ml LLOQ) developed to measure human interferon beta (IFN-Beta) in specific matrices (e.g. healthy and disease sera, plasma, tissue culture media (TCM)). These high sensitivity assays display no inhibition of human IFN-Beta detection in the presence of 3-Log excess of soluble IFN-Alpha/Beta Receptor 2 (sIFNAR2) protein, thus measuring “total” IFN-Beta.
41435 | 41415 | |
High Sensitivity Quantification | 2.34 pg/ml | 1.2 pg/ml |
Robust Sample Matrix Compatibility | Tissue Culture Media (TCM) | TCM, Plasma, Healthy, and Autoimmune Disease Sera |
Interference by sIFNAR2 | No | No |
Catalog No. | Description | Pack size |
41580-1 | Human IFNGR1 ELISA Kit (Serum, Plasma, Cell Lysate, TCM) | 1 x 96-well plate |
These Mouse IFN-Alpha All-Subtype ELISA kits are designed to provide global IFN-Alpha subtype detection (14 of 14). As multiple IFN-Alpha (IFNa, IFN-a) species are often present in biological samples, the ability to determine the total amount of IFN-Alpha subtypes is integral to a full understanding of IFN-Alpha’s role within the immune system.
These Mouse IFN-Beta ELISAs are developed to measure IFN-Beta in specific matrices (e.g. serum, plasma, tissue culture media (TCM)) at varying level of sensitivity.
Catalog No. | Description | Pack size |
42410-1 | Mouse IFN-Beta ELISA Kit, High Sensitivity (Serum, Plasma, TCM) | 1 x 96-well plate |
42410-2 | Mouse IFN-Beta ELISA Kit, High Sensitivity (Serum, Plasma, TCM) | 5 x 96-well plates |
42400-1 | Mouse IFN-Beta ELISA Kit (TCM, Serum) | 1 x 96-well plate |
42400-2 | Mouse IFN-Beta ELISA Kit (TCM, Serum) | 5 x 96-well plates |
This DIY Mouse IFN-Lambda ELISA kit is designed to provide detection of IFN-Lambda 2/3 (IL-28A/B) in tissue culture media (TCM).
Catalog No. | Description | Pack size |
62830-1 | DIY Mouse IFN-Lambda 2/3 (IL-28A/B) ELISA (TCM) | 15 x 96-wells |
This ELISA quantifies Cynomolgus and Rhesus IFN-Alpha 2 in serum, plasma, and tissue culture media (TCM).
Catalog No. | Description | Pack size |
46100-1 | Cynomolgus/Rhesus IFN-Alpha ELISA Kit (Serum, Plasma, TCM) | 1 x 96-well plate |
This ELISA quantifies Porcine IFN-Alpha in serum, plasma, and tissue culture media (TCM) with an LLOQ of 2.34 pg/ml.
Catalog No. | Description | Pack size |
47100-1 | Pig IFN-Alpha ELISA Kit (Serum, Plasma, TCM) | 1 x 96-well plate |
This ELISA quantifies Cynomolgus IFN-Beta in serum, plasma, and tissue culture media (TCM) with an LLOQ of 5.47 pg/ml.
Catalog No. | Description | Pack size |
46415-1 | Cynomolgus IFN-Beta ELISA Kit (Serum, Plasma, TCM) | 1 x 96-well plate |
Interleukin ELISA kits designed to provide accurate and sensitive quantification of endogenous levels in healthy and disease sera/plasma and tissue culture media samples.
This ELISA measures endogenous human IL-15 at or near basal levels with LLOQ of 0.51 pg/ml in serum, plasma, and tissue culture media.
Catalog No. | Description | Pack size |
41702-1 | Human IL-15 ELISA Kit, High Sensitivity (Serum, Plasma, TCM) | 1 x 96-well plate |
This ELISA is designed for accurate low-level quantitation of endogenous human IL-22 in healthy & disease sera/plasma, and tissue culture media (TCM) samples with an LLOQ of 0.78 pg/ml.
Catalog No. | Description | Pack size |
41701-1 | Pig IFN-Alpha ELISA Kit (Serum, Plasma, TCM) | 1 x 96-well plate |
At PBL, we understand the difficulties involved in working with a partner outside of your organization—because it’s something we’ve been doing for 30 years. Whether you have limited internal capacity or whether you’re seeking outside expertise in addressing specific experimental challenges, we know it takes an investment of your time and energy to establish a relationship and bring your projects to completion. But there’s one thing we do know, that’s been proven time and time again: PBL Assay Science is a partner that can take a great burden off your shoulders. We take the time to listen, to understand what you want to accomplish; we provide guidance from our deep knowledge base; we recommend only the work that your research requires; and we do all of this under the utmost confidentiality.
We don’t just run immunoassays and spit out results—we can be your ‘Thought Partner’. We can do the work. We can deliver results. Contact Us today to discuss your research needs. For simplified sourcing, we also work with Science Exchange and Scientist.com.
Here are some of the services we provide and an analyte selector tool to view immunoassay services available from PBL on different platforms:
Find out more in the sections below:
PBL can expedite your R&D work as our technologies and services can be tailored to meet your specific requirements under fit-for-purpose guidelines. For many of your sample testing and screening needs, PBL can help you measure your analyte(s) of interest. From state-of-the-art technologies quantifying into the femtogram/milliliter level to simultaneous detection of up to 9 analytes in a single well, PBL offers a multitude of options to fit your project needs.
We understand the value of your experimental samples and execute assays just as you would – consuming a minimum of sample while generating robust results. We can take on work you don’t have the capacity to handle yourself. Let us help you develop, customize, or just execute assays on your samples in a timely, professional manner.
High precision. Unprecedented sensitivity. Digital readout. Take your detection to the next level.
The unique immunoassay technology provided by the Simoa® platform allows PBL to deliver fg/ml level sensitivity for low abundance biomarkers in serum, plasma, and other matrices. Single Molecule Array technology traps a single bead in a femtoliter-sized well allowing for “digital” measurement of each bead. This approach can increase assay sensitivities several orders of magnitude over conventional bioassays.
The combination of this instrument’s markedly heightened sensitivity and its’ capacity for digital analyte measurement ensures accuracy and precision across a wide dynamic range and minimizes sample volume requirements.
Figure 1. Quanterix Simoa® Technology Overview
Unprecedented precision can be obtained using Simoa’s “digital” readings of single molecular events. In the image above, individual paramagnetic beads are trapped in femtoliter-sized wells, then sealed over and quantified by SIMOA image analysis.
Accurate and robust measurement. Increase your understanding. Detect at unprecedented levels.
The ability to accurately measure low-abundance analytes present in complex matrices is essential for the profiling and characterization of cytokines and other biomarker analytes. Employing proprietary single molecule counting technology with robust microparticle-based SMCxPRO® & Erenna® immunoassays, PBL’s cytokine detection services can provide scientists with sub-pg/ml level measurements of low-abundance analytes in healthy or disease sera and plasma.
An increased understanding of the role and regulation of cytokines in disease states results from greater profiling and characterization of their activities in biological responses. Singulex technology can be instrumental in furthering our collective understanding of low-abundance cytokines in complex matrices.
Figure 2. EMD Millipore Single Molecule Counting Technology Overview
Low abundance biomarkers in complex biological samples are transferred to a 96-well plate and incubated with capture antibody-coated microparticles. After washing and incubating with dye-labeled detection antibodes, wells are again washed to remove unbound detection antibodies. An elution buffer is added, and the eluate drawn into the instrument for single-molecule counting.
Broad dynamic range. Minimal background. High sensitivity. Enhanced signal capture achieved through luminescent detection.
PBL offers high precision protein quantification services for biomarker detection in a broad range of sample matrices for Human, Non-Human Primate (NHP), Mouse, Rat, and Canine samples. PBL utilizes MSD’s validated assay kits (V-Plex) to quantify up to 54 analytes within a single sample. This enables simultaneous comparison of the expression of pertinent cytokines, chemokines, and other biomarkers in samples from diseased and normal patients at different intervals.
Multiplex immunoassays on the MSD platform maintain the sensitivity and performance offered by singleplex ELISAs while providing additional benefits such as cost-savings and targeting of several related analytes in a single sample. The ability to quantify compatible analytes while requiring no more than 25 μl of neat sample ensures efficient use of precious sample.
Figure 3. MSD-ECL Technology Overview
Unique detection technology utilizes SULFO-TAGTM labels which emit light upon electrochemical stimulation. The intensity of light generated is captured via CCD camera and pixel intensities quantified. This system provides the basis for achieving measurement of a several log range of biomarker expression levels in a variety of matrices.
Sensitive detection and robust results. Dedicated, flexible workforce. Reliable, high-quality outcomes.
Take advantage of PBL ELISAs or other commercial ELISAs for a wide range of additional analytes using PBL’s services.
PBL ELISAs:
PBL ELISA kits are heterogeneous antibody sandwich immunoassays. The antigen is captured by an antibody immobilized to the wells in a microtiter plate and a secondary antibody is used to complete the sandwich. The detection system which utilizes horseradish peroxidase (HRP) and tetramethyl-benzidine (TMB) as the enzyme-substrate provides a sensitive and robust assay for the detection and quantification of interferons and cytokines.
PBL routinely runs ELISA studies for our clients for the detection and differentiation of interferons and cytokines in various sample matrices. We offer a range of heterogeneous immunoassay services for:
High sensitivity & specificity using low sample volumes. Cost-effective quantitation of multiple analytes.
PBL’s cost-effective multiplex ELISA services enable simultaneous detection of up to 16 different analytes in a single sample.
These ELISAs provide chemiluminescent results on each analyte and allow for a global understanding of ongoing immune responses in diseases ranging from cancer to autoimmunity. Evaluation of one given inflammatory molecule in the context of several others, repeated measurements of the same cytokine panels in the same subjects under different treatment assay conditions, and reliable detection of different proteins across a broad range of concentrations are just some of the benefits provided by this multiplex service.
Figure 4. Multiplex Technology Overview
PBL’s multiplex ELISAs employ a technology in which distinct capture antibodies are individually spotted into each well of a 96-well ELISA plate in a defined array. These plates are run similar to a normal ELISA run. An image of the plate is then taken using a CCD camera.
Using image analysis software to perform subsequent analysis, the chemiluminescent results for each analyte allow for a deeper understanding of the cytokine profiles of the samples.
PBL’s reagent development services offer customized production of cytokines, interferons, antibodies, and other proteins.
With a wealth of knowledge on immunological interactions, we offer protein biophysical characterization services which can determine the kinetic characterization of protein-protein interactions. These services include determination of:
PBL offers biophysical characterization of antibody affinity for a ligand or the measurement of antigen:antibody Kon/Koff rates. To accelerate assay development, we also determine which antibodies bind to antigens in a sandwich format. Binning— determination of antibodies which bind to non-overlapping epitopes—is performed using multiple hybridoma clones.
The graph below shows the association and dissociation of IFN to a surface-immobilized antibody as determined by real time Biolayer Interferometry (BLI) using varying concentrations of IFN. The raw data is shown in blue and the model response in red.
Figure 1. IFN Binding to and Dissociation from a Surface-Immobilized Monoclonal Antibody Evaluated by Bio-Layer Interferometry (BLI)
PBL offers custom antibody labeling using a range of dyes and labels including FITC, R-PE, biotin, etc.
The graph below shows an example of a R-Phycoerythrin (PE) Conjugation of a Mouse Monoclonal Antibody.
Figure 2. Flow cytometry analysis of KG-1 cells showed expression of Human Interferon Alpha/Beta Receptor. Isotype control (shaded histogram) and human interferon alpha/beta receptor (un-shaded histogram). (Catalog No. 21370-3)
Cell-based assay tools are key to understanding cellular mechanisms in a biologically relevant context. PBL offers a targeted portfolio of cell-based assay services to provide you with the most relevant information and facilitate advancement of your research.
Whatever your cell-based study needs, PBL will work with you to determine the most suitable assay program to meet your goals. PBL’s services team is a trusted partner of midsize and major biotech and pharma companies worldwide.
Selected capabilities:
Growth promotion and inhibition assays are often used to measure cytokine and drug activity profiles. Such Proliferation and Anti-Proliferation (AP) assays utilize a variety of cell lines and protein or small molecule stimuli to address specific applications and clinical indications. EC50 or IC50 results are provided.
Figure 1 shows OVCAR-3 grown in the presence of IFN-alpha. Cellular anti-proliferation was quantified using soluble tetrazolium reagent. Figure 2 shows TF-1 grown in the presence of GM-CSF. Cellular proliferation was quantified using soluble tetrazolium reagent. For both graphs, the quantity of reduced reagent product is directly proportional to viable cell number.
Figures 1 and 2. Growth Inhibition and Promotion Assays
Accurate measurement of the ability of a sample to induce cytokine production and/or release from cell lines or isolated donor cells is the standard assay for certain applications, such as measurement of IL-18 activity.
Figure 3 shows a natural killer cell model, NK-92, stimulated to produce IFN-Gamma by incubation with Type I IFNs. The data is graphed as a function of IFN-alpha concentration in the bioassay.
Figure 3. Cytokine Secretion Assay
The standard bioassay used to determine the biological activity of interferon (IFN) encompasses measurement of the protection of cells from the cytopathic effect (CPE) of certain viruses. CPE assay services may be used to measure the antiviral activity of IFN-α, β, ω, γ, and λ in human samples, as well as in a variety of other species, and in multiple matrices.
CPE assays are inherently complex due to the metabolic state of cells, virus replication, and the ability of IFN to protect cells. Our years of knowledge and expertise in CPE assays will reduce variability and provide you with reproducible quality results.
Results are provided either as a graphical representation of dye binding which allows slope and parallel line analysis, or visually determined from microscopic examination of the CPE and determination of the dilution of test samples which protects 50% of the cells.
Figure 4 to the right shows IFN-beta titrated in a CPE assay on A549 cells with EMCV. In this antiviral assay, the EC50 is approximately 1 unit/ml of interferon. Units of IFN activity were determined colorimetrically with respect to an international reference standard for human IFN.
Figure 4. Human IFN-Beta AVA Standard in CPE Assay
The standard method of accurately determining whether a sample may inhibit the biological activity of cytokines is the neutralization assay. Results, provided either as a visual read or in a graphical format, reveal the ability of a sample to block the activity of IFN added at a specific concentration which provides 100% cell protection.
May be used as an anti-drug antibody (ADA) assay for certain therapeutics.
Figure 5 to the right shows representative neutralization curves of two different MAbs to IFN in a CPE assay to determine neutralization titer. One neutralization unit (NU) is the amount of antiserum or antibody (NAb) required to neutralize 1 unit of human IFN to a 50% endpoint. NU are determined with respect to the international reference standard.
Figure 5. Monoclonal Antibody Titration (Neutralizing Antibody Assay)
As the drug discovery pathway shifts toward specifically targeted pathways and molecules, model systems continue to increase in importance. The ease of use and versatility of mouse models in the study of human cancer, infectious disease and autoimmunity provides understanding into the etiology of these diseases. Data obtained from studies using mouse models can provide insight into potential clinical side effects and the pathology of diseases.
PBL Assay Science provides a comprehensive mouse product line manufactured to the highest standards of quality, consistency and purity. PBL’s products are designed to meet your scientific needs by providing superior quality and performance to ensure reliable and reproducible results.
Figure 1. Comparison of Mu Alpha A and Mu Alpha 4 Antiviral Activity
Figure 2. Recovery of Mu Alpha A in 50% Serum in Mu Alpha ELISA (42120)
12100-1 | Mouse IFN Alpha A | 1 x 105 U |
12105-1 | Mouse IFN Alpha 1 | 1 x 105 U |
12115-1 | Mouse IFN Alpha 4, mammalian | 1 x 105 U |
12125-1 | Mouse IFN Alpha 11 | 1 x 105 U |
12130-1 | Mouse IFN Alpha 13 | 1 x 105 U |
12185-1 | NEW C12R Mouse IFN Alpha Decoy Receptor, neutralizing | 10 μg |
12185-2 | NEW C12R Mouse IFN Alpha Decoy Receptor, neutralizing | 100 μg |
12400-1 | Mouse IFN Beta | 1 x 105 U |
12401-1 | Mouse IFN Beta (carrier-free) | 1 x 105 U |
12405-1 | Mouse IFN Beta, mammalian | 1 x 105 U |
12410-1 | Mouse IFN Beta, mammalian (carrier-free) | 1 x 106 U |
12820-1 | Mouse Interleukin-28b/IFN Lambda 3 | 25 μg |
12821-1 | Mouse Interleukin-28b/IFN Lambda 3 (carrier-free) | 25 μg |
22100-1 | Anti-Mouse IFN Alpha, Clone RMMA-1 (MAb) | 250 μg |
22100-3 | FITC Conjugated Anti-Mouse IFN Alpha, Clone RMMA-1 (MAb) | 25 μg |
22400-1 | Anti-Mouse IFN Beta, Clone RMMB-1 (MAb) | 250 μg |
22400-3 | FITC Conjugated Anti-Mouse IFN Beta, Clone RMMB-1 (MAb) | 25 μg |
22500-1 | Anti-Mouse IFN Gamma, Clone RMMG-1 (MAb) | 500 μg |
32100-1 | Anti-Mouse IFN Alpha, Rabbit Serum (PAb) | 2 x 104 U |
32120-1 | Anti-Mouse IFN Alpha, Chicken IgY, Purified (PAb) | 500 μg |
32400-1 | Anti-Mouse IFN Beta, Rabbit Serum (PAb) | 2 x 104 U |
32401-1 | Anti-Mouse IFN Beta, Rabbit IgG, Protein A Purified (PAb) | 2 x 104 U |
32500-1 | Anti-Mouse IFN Gamma, Rabbit Serum (PAb) | 2 x 104 U |
42120-1 | VeriKine Mouse IFN Alpha ELISA Kit | 1 plate |
42120-2 | VeriKine Mouse IFN Alpha ELISA Kit | 5 plate |
42115-1 | NEW VeriKine-HS Mouse IFN Alpha All-Subtype ELISA Kit | 1 plate |
42400-1 | VeriKine Mouse IFN Beta ELISA Kit | 1 plate |
42400-2 | VeriKine Mouse IFN Beta ELISA Kit | 5 plate |
42410-1 | VeriKine-HS Mouse IFN Beta Serum ELISA Kit | 1 plate |
42410-2 | VeriKine-HS Mouse IFN Beta Serum ELISA Kit | 5 plate |
52500-1 | NEW VeriPlex Mouse Cytokine 9-Plex ELISA Kit | 1 plate |
62830-1 | DIY Mouse IFN Lambda 2/3 (IL-28A/B) ELISA | Materials for 15 x 96 wells |
High quality Interferon Gamma products from PBL Assay Science:
Figure 1. Chromatographic profile of IFN-γ showing dimerization and low aggregation
Figure 2. PBL IFN-γ and international gamma standard exhibit comparable antiviral activities
11500-1 | Human IFN Gamma | 50 μg |
11500-2 | Human IFN Gamma | 100 μg |
13500-1 | Rat IFN Gamma | 10 μg |
21500-1 | Anti-Human IFN Gamma, Clone MMHG-1 (MAb) | 500 μg |
21550-1 | Anti-Human IFN Gamma, Clone MMHG-2 (MAb) | 100 μg |
21585-1 | Anti-Human IFN Gamma Receptor Chain 2, Clone MMHGR-2 (MAb) | 250 μg |
22500-1 | Anti-Mouse IFN Gamma, Clone RMMG-1 (MAb) | 500 μg |
31500-1 | Anti-Human IFN Gamma, Rabbit Serum (PAb) | 2 x 104 U |
32500-1 | Anti-Mouse IFN Gamma, Rabbit Serum (PAb) | 2 x 104 U |
41500-1 | VeriKine Human IFN Gamma ELISA Kit | 1 plate |
41580-1 | NEW VeriKine Human IFN Gamma Receptor 1 ELISA Kit | 1 plate |
Non-human primates are considered a preferred model for the study of human diseases due to a close phylogenetic relationship to humans. The model is crucial to the elucidation of pathological mechanisms and may enable the development of novel diagnostic and therapeutic tools. Studies of innate and adaptive immunity, pharmacodynamics (PD), and immunotoxicology of interferon stimulating/inhibiting molecules, as well as Emerging Infectious Disease (EID) models, can all be further advanced with an interferon immunoassay that is designed specifically for NHP.
PBL now offers ELISAs for the specific detection of NHP IFN-Alpha and IFN-Beta in a variety of sample matrices. Visit our website or contact us for more information on these kits!
Product Information:
VeriKineTM Cynomolgus/Rhesus Interferon Alpha Serum ELISA (Cat. No. 46100-1)
Compatibility: Serum, Plasma, Cell Culture Supernatant
Assay Range: 25 – 1600 pg/ml
Figure 1. Standard Curve in Different Sample Matrices
Figure 2. Specifically designed for detecting NHP IFN-α Greater NHP IFN-α detection sensitivity and matrix compatibility
Product Information:
VeriKineTM Cynomolgus Interferon Beta ELISA (Cat. No. 46415-1)
Compatibility: Serum, Plasma, Cell Culture Supernatant
Assay Range: 5.47 – 350 pg/ml
Figure 3. Typical standard curve from 5.47 to 350 pg/ml
Figure 4. Performance specifications at three different concentrations
Anti-Human Interferon Alpha/Beta Receptor Chain 2 (IFNAR2), Clone MMHAR-2 (MAb)
Figure 1. Mouse MAb to Human IFN α/β Receptor 2 (MMHAR-2)
Anti-Human Interferon Lambda Receptor 1, Clone MMHLR-1 (MAb)
Figure 2. Neutralizing MAb against IFNLR1
Sample | EC50 (ng/ml) |
10 ng/ml | L1 31.3 |
10 ng/ml | L2 54.3 |
3 ng/ml | L3 22.0 |
C12R Mouse Interferon Alpha Decoy Receptor
Figure 3. C12R Neutralization of Mouse IFN α Subtypes on L929 Cells
Anti-Human Interferon Alpha, Sheep Serum (PAb)
Figure 4. Neutralization of Human IFN α subtypes on A549 cells
< 1 EU/μg
Carrier protein (PBS with 0.1% BSA) was added to provide extra stability to the cytokine proteins. However, in certain applications, such as in vivo injection, conjugation, or surface binding, carrier protein may interfere.
The formula to use to convert S.A. to pg/ml is as follow: [(1 x 10E+09)/(Lot specific activity in units/mg)] x [Lot-specific concentration in units/ml]
Culture medium supplemented with serum. Interferon beta proteins are unstable at diluted concentrations. Unless formulation work has been done to verify stability, do not dilute carrier-free solution to protein concentration below 100 μg/ml.
Acetic acid prevents aggregation of interferon beta proteins in this particular product formulation.
PBL does not offer any controls for its antibodies at the current time.
For monoclonal antibodies, use normal antibody from the same species and the same isotype. For example, if a MAb is a murine IgG2A, use the normal equivalent as the negative control. Some polyclonal antibodies from PBL are unpurified sera. Therefore, investigators should use normal unpurified serum from the appropriate species as their negative control.
User cell lines vary so there is no specific answer to this question. However, the general rule is 70 fold excess in mass should be used for neutralizing interferon. It is recommended to quantify the amount of interferon via technique such as ELISA. It is also recommended to allow time (1-2 hours in general) for the antibody to neutralize the interferon before adding the virus.
he viral challenge assay is used to test antibodies for neutralization activity. The assay measures the ability of the antibody to negate the protective effects of the interferon against the protective effects of the interferon against the viral challenge.
All PBL ELISA kits are constructed with carefully selected proprietary antibodies and optimized reagents.
PBL offers a range of assay kits that are specifically designed for serum/plasma human interferon alpha (41110, 41115), human interferon beta (41415), mouse interferon beta (42410, 42400), cynomolgus interferon alpha (46100), human IFNs and cytokines (51500).
Due to lot-specific optimization of our ELISA kit reagents, they are not sold separately.
To optimize each lot of kits, PBL modifies the concentration of the reagents to achieve a standard curve that will meet our specific range and signal to noise requirements.
No. Reagent concentration is optimized according to lot. Reagents from different lot can not be used as substitutes without affecting the overall performance of the kit.
Stratech Scientific have been successful in a recent antibodies tender from the Southern Universities Purchasing Consortium. In the award criterion Read More…
PBL Assay Science’s VeriPlex ELISAs are fully quantitative, high throughput multiplex ELISA kits that provide simultaneous quantification and detection of Read More…